Table 1.
| ETV | TDF | TAF | Pegylated IFN | |
|---|---|---|---|---|
| HBeAg‐positive patients | ||||
| At week 48 or 52 | ||||
| Undetectable HBV DNA | 67 | 67‐76 | 64 | 25 |
| HBeAg seroconversion | 21 | 12‐21 | 10 | 27 |
| HBsAg loss | 2 | <1‐3 | 1 | 3 |
| During extended treatment or follow‐up † | ||||
| Undetectable HBV DNA | 94 (5) | 97 (5) | 73 (2) | 13 (4.5) |
| HBeAg seroconversion | 41 (5) | 40 (5) | 18 (2) | 37 (4.5) |
| HBsAg loss | 5 (5) | 10 (5) | 1 (2) | 8 (4.5) |
| HBeAg‐negative patients | ||||
| At week 48 or 52 | ||||
| Undetectable HBV DNA | 90 | 93 | 94 | 63 |
| HBsAg loss | <1 | 0 | 0 | 4 |
| During extended treatment or follow‐up † | ||||
| Undetectable HBV DNA | NA | 99 (5) | 90 (2) | 18 (4) |
| HBsAg loss | NA | 0 (5) | <1 (2) | 8 (4) |
Abbreviation: NA, not available.
*
Responses presented as %.
†
Time point in which response was assessed in years while on treatment for ETV, TDF, or TAF and during off‐treatment follow‐up for pegylated IFN.